Evidence map›Paper›PMID 35837987›Full record

ReviewJournal of clinical laboratory analysis2022

Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.

Sai Chen, Hefei Ren, Xiaomin Zhang, Liu Chang, Zhenhua Wang, Hongkun Wu, Jiafeng Zhang, Jigang Ren, Lin Zhou

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. NPeerJ · 2023
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sai ChenDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.ORCID https://orcid.org/0000-0002-8564-5443
Hefei RenDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.ORCID https://orcid.org/0000-0003-0946-5683
Xiaomin ZhangDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Liu ChangDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Zhenhua WangDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Hongkun WuDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Jiafeng ZhangDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Jigang RenDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Lin ZhouDepartment of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.ORCID https://orcid.org/0000-0002-2549-2721
Shanghai Changzheng Hospital · CN

Funding

Leading Talent Project of Shanghai Huangpu District 2020-1-28National Natural Science Foundation of China 82072371National Natural Science Foundation of China 82102482Shanghai Health and Medical Development Foundation 201972Shanghai Science and Technology Committee 21ZR1478200
6 · The paper itself

Abstract

backgroundN6-methyladenosine (m6A) is the addition of a methyl group on the N6 position of adenosine and is the most prevalent and abundant epigenetic modification in eukaryote mRNA. m6A marks are added to mRNA by the m6A methyltransferase complex ("writers"), removed by m6A demethylases ("erasers"), and recognized by m6A-binding proteins ("readers"). Recent evidence has shown that the m6A modification plays a crucial role in the pathogenic mechanism and malignant progression of pancreatic cancer, with roles in cell survival, proliferation, migration, invasion, tumor metastasis, and drug resistance.

methodsLiterature was searched in Pubmed and Web of Science for the following keywords: "N6-methyladenosine", "pancreatic cancer", "epigenetic modification", "immunotherapy".

resultsAmong classical m6A regulators, while METTL3, METTL14, WTAP, FTO, YTHDF2, IGF2BP1-3, hnRNPC, and NKAP are upregulated in pancreatic cancer, METTL16 and ALKBH5 are downregulated in pancreatic cancer. m6A modification has been investigated in pancreatic cancer therapy.

conclusionDysregulated m6A and its related factors in pancreatic cancer cells and patients indicate their potential values as novel biomarkers in pancreatic cancer diagnosis and targeted therapy.

Indexed as

MethyltransferasesPancreatic NeoplasmsAdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTOHumansRepressor ProteinsRNA, MessengerAdenosineAlpha-Ketoglutarate-Dependent Dioxygenase FTOFTO protein, humanMethyltransferasesMETTL16 protein, humanMETTL3 protein, humanNKAP protein, humanN-methyladenosineRepressor ProteinsRNA, Messengerclinical valueepigenetic modificationimmunotherapyN6-methyladenosinepancreatic cancer

Identifiers

PMID35837987
PMCPMC9459282
OpenAlexW4285590705

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.